Gynecologic Cancer-Refresher 2017

The first gynecologic cancer session, Updates in Endometrial Cancer will review the use of new clinical paradigms including the use of nomogram assessment to assist with medical decision making; the utilization of Intensity Modulated Radiation Therapy (IMRT) and complex 3-D conformal radiation using image guided techniques.  Knowledge of treatment paradigms with radiation and chemotherapy is critical for the treatment of GYN cancer patients. Dedicated teaching of the relevant concepts and literature will help to maximize local control and minimize complications. The use of CT and MR-based brachytherapy planning has led to the need to define a dose specification target volume along with the organs at risk.

The second session, Updates in Cervical Cancer, will review the use of new clinical paradigms including the use of intensity modulated radiation therapy and modern vaginal brachytherapy. We will also discuss the use of combined chemotherapy and radiotherapy in advanced endometrial cancer.

This activity is available from September 14, 2017, through 11:59 p.m. Eastern time on September 13, 2020.

This activity was originally recorded at ASTRO’s 2017 Refresher, April 7-9, 2017 in Chicago, IL.
 

Target Audience

This program is designed to meet the interest of radiation oncologists and radiation oncology residents.

Learning Objectives

Upon completion of Updates in Endometrial Cancer, participants should be able to:

  • Discuss the standard therapeutic approach to endometrial cancer patients most commonly encountered in a radiation oncology clinic.
  • Articulate the radiobiological and physical principles that inform current clinical therapeutic paradigms.
  • Discuss current state of the art vaginal brachytherapy.

Upon completion of Updates in Cervical Cancer, participants should be able to:

  • Apply nomograms for GYN cancers during patient consultations in order to provide more accurate prognostic information to patients.
  • Identify the importance of image guided brachytherapy.
  • Discuss IMRT appropriately and understand indications for IMRT.
Course summary
Available credit: 
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
  • 1.50 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.

Course opens: 
09/14/2017
Course expires: 
09/13/2020
Cost:
$105.00
Rating: 
0
  • William Small, MD, FASTRO, is employed at Loyola University Medical Center and has no financial relationships with a commercial interest.
  • Akila Viswanathan, MD, MPH, is employed by Johns Hopkins University and has no financial relationships with a commercial interest.

The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.

Disclosure link: 
Committee Disclosure

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

 

Available Credit

  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
  • 1.50 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.

Price

Cost:
$105.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

  • Nonmember: $105
  • Member: $55

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

 

 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.